Xilio Therapeutics XLO
NASDAQ XLO
$8.40 -0.14 (-1.64%)
As of: Oct 21, 2026 · 3:59 PM EDT

Xilio Therapeutics (XLO) Preferred Stock Liabilities (2020 - 2021)

Updated

Xilio Therapeutics' Preferred Stock Liabilities was $222.89 million in Q3 2021, up 185.7% from $78 million a year earlier and unchanged from the prior quarter.

Analysis

Xilio Therapeutics (XLO) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Preferred Stock Liabilities at Xilio Therapeutics came in at $78 million.

  • Per Business Quant data, XLO's Preferred Stock Liabilities in the three quarters before Q3 2021 was $222.89 million (Q2 2021), $222.89 million (Q1 2021) and $78 million (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Xilio Therapeutics 162.81 Mn -364.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 222.89 Mn
Jun 30, 2021 222.89 Mn
Mar 31, 2021 222.89 Mn
Dec 31, 2020 78.00 Mn
Sep 30, 2020 78.00 Mn
API Access

Xilio Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=XLO&period=max&api_key=YOUR_API_KEY